Intralesional methotrexate for treatment of keratoacanthoma and well-differentiated squamous cell carcinoma

In the most recent “Guidelines of care for the management of cutaneous squamous cell carcinoma” by Kim et al published in the Journal of the American Academy of Dermatology, intralesional methotrexate was not included as a potential alternative to surgical excision. This case series presents three patients with ke ratoacanthoma and well-differentiated squamous cell carcinomas that showed complete clinical resolution with two to three injections of 25 mg/mL methotrexate, each approximately two weeks apart.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research